文献速递淋巴瘤

难治性弥漫性大B细胞淋巴瘤的结局:国际SCHOLAR-1研究结果

Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study.
PubMed 文献 · Blood · 2017-08-03

SCHOLAR-1是一项国际多队列回顾性非霍奇金淋巴瘤研究,汇总2项3期临床试验和2个观察性队列数据。在861例患者中,636例符合难治性弥漫性大B细胞淋巴瘤标准。难治患者对下一线治疗的客观缓解率为26%(完全缓解率7%),中位总生存期6.3个月,2年时20%患者存活。各亚组和研究队列结局一致地差。

要点

  • 难治性DLBCL对下一线治疗的客观缓解率为26%,完全缓解率仅7%。
  • 难治性DLBCL中位总生存期6.3个月,2年时20%患者存活。
  • 结局在患者亚组和研究队列间一致地差。

核心结论

  • SCHOLAR-1是迄今最大的患者水平汇总回顾性分析,用于描述难治性DLBCL人群的缓解率和生存。
  • 难治性DLBCL患者对下一线治疗的客观缓解率为26%(完全缓解率7%),中位总生存期6.3个月,2年时20%患者存活。
  • 结局在患者亚组和研究队列间一致地差。

研究设计与样本

  • SCHOLAR-1为国际多队列回顾性非霍奇金淋巴瘤研究,汇总2项3期临床试验(Lymphoma Academic Research Organization-CORAL和Canadian Cancer Trials Group LY.12)及2个观察性队列(MD Anderson Cancer Center和University of Iowa/Mayo Clinic Lymphoma Specialized Program of Research Excellence)的数据。
  • 共861例患者,其中636例基于难治性疾病纳入标准被纳入。
  • 难治性定义为化疗期间任何时间点最佳疗效为疾病进展或疾病稳定(一线治疗>4周期或后线治疗2周期)或自体造血干细胞移植后≤12个月复发。
  • 缓解率和总生存期从难治性疾病挽救治疗启动时开始估计。

主要发现

  • 难治性DLBCL患者对下一线治疗的客观缓解率为26%,完全缓解率为7%。
  • 难治性DLBCL患者中位总生存期为6.3个月。
  • 难治性DLBCL患者2年时存活比例为20%。
  • 结局在患者亚组和研究队列间一致地差。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of non-Hodgkin lymphoma. Although 5-year survival rates in the first-line setting range from 60% to 70%, up to 50% of patients become refractory to or relapse after treatment. Published analyses of large-scale outcome data from patients with refractory DLBCL are limited. SCHOLAR-1, an international, multicohort retrospective non-Hodgkin lymphoma research study, retrospectively evaluated outcomes in patients with refractory DLBCL which, for this study, was defined as progressive disease or stable disease as best response at any point during chemotherapy (>4 cycles of first-line or 2 cycles of later-line therapy) or relapsed at ≤12 months from autologous stem cell transplantation. SCHOLAR-1 pooled data from 2 phase 3 clinical trials (Lymphoma Academic Research Organization-CORAL and Canadian Cancer Trials Group LY.12) and 2 observational cohorts (MD Anderson Cancer Center and University of Iowa/Mayo Clinic Lymphoma Specialized Program of Research Excellence). Response rates and overall survival were estimated from the time of initiation of salvage therapy for refractory disease. Among 861 patients, 636 were included on the basis of refractory disease inclusion criteria. For patients with refractory DLBCL, the objective response rate was 26% (complete response rate, 7%) to the next line of therapy, and the median overall survival was 6.3 months. Twenty percent of patients were alive at 2 years. Outcomes were consistently poor across patient subgroups and study cohorts. SCHOLAR-1 is the largest patient-level pooled retrospective analysis to characterize response rates and survival for a population of patients with refractory DLBCL.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Crump M, Neelapu SS, Farooq U, et al. Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study. Blood. 2017. PMID: 28774879. doi:10.1182/blood-2017-03-769620

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。